Targeted Oncology - Immunotherapy, Biomarkers, and Cancer …
Assessing Targeted PET Imaging for Advanced Rectal Cancer. By Jordyn Sava. October 3rd 2024. In an interview with Targeted Oncology, Jeffrey Wong, MD, discussed the potential and future directions of Cu 64 anti-CEA M5A as a PET imaging agent for advanced rectal cancer.
Sequencing Matters: Giving Radium-223 Prior to Docetaxel Leads …
Sep 16, 2024 · The use of radium-223 (Xofigo) prior to docetaxel in symptomatic metastatic castration resistant prostate cancer (mCRPC) demonstrated better quality of life (QOL) and tolerability scores over the converse sequence of docetaxel prior to radium-223, according to findings from the phase 2 RAPSON trial (NCT03230734).1 Results also demonstrated no difference between the treatment arms for ...
High-Dose Radiation Plus Long-Term ADT Improves Survival in …
Jan 25, 2024 · Utilizing a higher dose of radiation therapy in combination with the long-term use of androgen deprivation therapy (ADT) improved survival outcomes after 10 years of follow-up in patients with high-risk prostate cancer, according to long-term results from the GETUG-AFU 18 trial (NCT00967863) presented at the 2024 ASCO Genitourinary Cancers ...
FDA Approves Ribociclib With an Aromatase Inhibitor in Early …
Sep 17, 2024 · "The FDA approval of [ribociclib] for this early breast cancer population, including those with [node-negative] disease, is a pivotal moment in improving our approach to care," Dennis J. Slamon, MD, director of clinical/translational research, UCLA Jonsson Comprehensive Cancer Center and chairman of the Board of Translational Research In Oncology and NATALEE trial lead investigator, said in a ...
FDA Grants Fast Track Designation to ICT01 Plus Azacitidine and ...
Sep 18, 2024 · ICT01 is a humanized anti-butyrophilin (BTN) 3A monoclonal antibody. The phase 1/2a EVICTIONtrial (NCT04243499) is evaluating ICT01. ICT01 plus azacitidine and venetoclax has earned FDA fast track designation for the treatment of patients with AML who are 75 years of age or older or cannot tolerate standard induction chemotherapy. 1.
FDA Clears IND of VNX-101 in CD19+ Acute Lymphoblastic …
Sep 12, 2024 · The FDA has cleared an investigational new drug (IND) application for VNX-101 for the treatment of CD19-positive acute lymphoblastic leukemia (ALL). VNX-101 is the first gene therapy product candidate from Vironexis Biotherapeutics. Enrollment of a phase 1/2 trial (NCT06533579) evaluating VNX-101 is expected to begin in the fourth quarter of 2024.
T-DXd Maintains QOL, Delays Pain Deterioration in HR+/HER2 …
Sep 15, 2024 · The median time to pain deterioration showed the most significant improvement for T-DXd at 22.0 months (95% CI, 17.2-not reached) vs 6.3 months (95% CI, 4.8-9.6) for TPC (HR, 0.51; 95% CI, 0.39-0.65). “The global health/QOL was observed over 31 weeks for both arms. The QOL scores did not change from the baseline to a clinically significant ...
New Treatment Potential for TP53-Mutated MCL - Targeted …
Dec 20, 2023 · The targeted therapy combination of obinutuzumab (Gazvya), zanubrutinib (Brukinsa), and venetoclax (Venclexta; BOVen) showed promising results in treating P53-mutant mantle cell lymphoma (MCL), a difficult-to-cure form of cancer.Patients receiving BOVen achieved high rates of survival and disease-free status after 2 years, exceeding expectations for this aggressive subtype.
FDA Grants Orphan Drug Designation to CF33-hNIS in …
Sep 18, 2024 · The FDA has granted an orphan drug designation to CF33-hNIS, a novel chimeric oncolytic therapy, in cholangiocarcinoma. 1. FDA orphan drug status is granted to encourage the development of treatments for rare diseases affecting fewer than 200,000 individuals in the US. With this designation, Imugene, the sponsor is offered several incentives ...
Lenvatinib-Pembrolizumab Duo Delivers Impressive Results in …
Sep 18, 2024 · The combination of lenvatinib and pembrolizumab showed promising results in treating recurrent endometrial carcinoma, demonstrating significant antitumor activity and improved survival rates compared to standard therapy. Microscopic image of endometrial cancer cell - Generated with Google Gemini AI. Lenvatinib (Lenvima) in combination with ...